92472-37-2

Usage

Uses

Used in Pharmaceutical Research:
(4aR,4bS,6aS,7S,9aS,9bR)-7-hydroxy-1,4a,6a-trimethyl-1,3,4,4a,4b,5,6,6a,7,8,9,9a,9b,10-tetradecahydro-2H-indeno[5,4-f]quinolin-2-one is used as a potential candidate for pharmaceutical research due to its structural complexity and the presence of functional groups that could interact with biological targets.
Used in Drug Development:
(4aR,4bS,6aS,7S,9aS,9bR)-7-hydroxy-1,4a,6a-trimethyl-1,3,4,4a,4b,5,6,6a,7,8,9,9a,9b,10-tetradecahydro-2H-indeno[5,4-f]quinolin-2-one is used as a potential candidate for drug development, as its unique structure and functional groups may offer novel therapeutic opportunities for treating various diseases and conditions.

Upstream product

• 7430-16-2 3-((3S,3aS,5aS,6R,9aS,9bS)-3-acetoxy-3a,6-dimethyl-7-oxododecahydro-1H-cyclopenta[a]naphthalen-6-yl)propanoic acid 
• 593-51-1 methylamine hydrochloride 
• 1759-35-9 5-oxo-A-nor-3,5-seco-17β-hydroxy-androstan-3-oic acid 
• 74-89-5 methylamine 
• 6218-23-1 17β-acetoxy-4-methyl-4-aza-androst-5(6)-en-3-one 
• 58-22-0 testosterone 

Downstream Products

• 95270-47-6 17β-hydroxy-N-methyl-4-aza-5-androsten-3-one p-phenoxyacetate 
• 95270-48-7 17β-hydroxy-N-methyl-4-aza-5-androsten-3-one p-phenylacetate 

Relevant academic research and scientific papers

Design, synthesis, and biological evaluation of 16-substituted 4-azasteroids as tissue-Selective Androgen Receptor Modulators (SARMs)

A novel series of 16-substituted-4-azasteroids has been identified as potential tissue-selective androgen receptor modulators. These ligands display potenthARbinding and agonist activity, low virilizing potential, and good pharmacokinetic profiles in dogs

4-aza steroids

The invention related to 4-aza-17β-(cyclopropoxy)-androst-5α-androstan-3-one, 4-aza-17β-(cyclopropylamino)-androst-4-en-3-one and related compounds and to compositions incorporating these compounds, as well as the inhibition of C17-20lyase, 5α-reductase and C17α-hydroxylase and to the use of these compounds in the treatment of androgen and estrogen mediated disorders, including benign prostatic hyperplasia, androgen mediated prostate cancer, estrogen mediated breast cancer and to DHT-mediated disorders such as acne. Disorders relating to the oversynthesis of cortisol, for example, Cushing's Syndrome, are also included. The treatment of androgen-dependent disorders also includes a combination therapy with known androgen-receptor antagonists, such as flutamide. The compounds of the invention have the following general formula:

17-BETA-CYCLOPROPYL(AMINO/OXY) 4-AZA STEROIDS AS ACTIVE INHIBITORS OF TESTOSTERONE 5-ALPHA-REDUCTASE AND C17-20-LYASE

The invention related to 4-aza-17 beta -(cyclopropoxy)-androst-5 alpha -androstan-3-one, 4-aza-17 beta -(cyclopropylamino)-androst-4-en-3-one and related compounds and to compositions incorporating these compounds, as well as the inhibition of C17-20 lyase, 5 alpha -reductase and C17 alpha -hydroxylase and to the use of these compounds in the treatment of androgen and estrogen mediated disorders, including benign prostatic hyperplasia, androgen mediated prostate cancer, estrogen mediated breast cancer and to DHT-mediated disorders such as acne. Disorders relating to the oversynthesis of cortisol, for example, Cushing's Syndrome, are also included. The treatment of androgen-dependent disorders also includes a combination therapy with known androgen-receptor antagonists, such as flutamide. The compounds of the invention have general formula (I).

Inhibitors for testosterone 5α-reductase activity

Inhibitors of testosterone 5α-reductase activity, for example those of formula: STR1 wherein novel substituents are provided at the R 4, R 6, R 7, R 17α and/or R 17β positions are useful for the treatment of diseases whose progress is aided by activation of androgen receptors, e.g., prostate cancer, benign prostatic hyperplasia, acne, seborrhea, hirsutism, androgenic alopecia and the like.

Azasteroids as Inhibitors of Rat Prostatic 5α-Reductase

A series of A-ring heterocyclic steroids has been prepared and tested for inhibition of rat prostatic steroid 5α-reductase in vitro.Strinkingly high inhibitory activity was found with a group of 17β-substituted 4-methyl-4-aza-5α-androstan-3-ones.These compounds were prepared from 3-keto-Δ4-precursors by oxidative (O3 or NaIO4-KMnO4) A-ring cleavage followed, in turn, by ring closure with an amine and hydrogenation over platinum catalyst.Other A-ring azasteroids were made by Beckmann rearrangement of oximes of 2-oxo-A-nor-, 3-oxo- and 4-oxo-5α-androstanes.An A-nor-2-oxo-3-azasteroid was prepared by oxidative decarbonylation of a precursor 2,3-dioxo-4-azasteroid with m-chloroperbenzoic acid.A-ring modifications of the 4-azasteroids included Δ1-unsaturation, 2- and 4-substituents, and 3-carbonyl replacements.Side chains at the 17-position were varied with an emphasis on carboxylate derivatives (salts, esters, and amides).

Antineoplastic agents. V. Nitrogen mustards of systematically modified steroidal ring A lactams

The p-[N,N-bis(2-chloroethyl)amino]phenylacetates and p-[N,N-bis(2-chloroethyl)amino]phenoxyacetates of seven 17 β-hydroxylated steroidal ring A lactams have been prepared and their biological activity evaluated against mouse leukemia L1210 and, for four